22 March 2018  
EMA/CHMP/171802/2018  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Ivemend 
fosaprepitant 
On 22 March 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Ivemend. The marketing authorisation holder for this medicinal product is Merck Sharp & Dohme Limited. 
The CHMP adopted an extension to the existing indication as follows 2: 
"Prevention of acute and delayed nausea and vomiting associated with highly emetogenic 
cisplatin-based cancer chemotherapy in adults. 
Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in 
adults 
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer 
chemotherapy in adults and paediatric patients aged 6 months and older. 
IVEMEND 150 mg is given as part of a combination therapy.” 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
                                                
